FTO T/A and peroxisome proliferator-activated receptor-γ Pro12Ala polymorphisms but not ApoA1 -75 are associated with better response to lifestyle intervention in Brazilians at high cardiometabolic risk

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 3, 2013, Pages 169-176

  Curti, Maira L R ^a   Rogero, Marcelo M ^a   Baltar, Valéria Troncoso ^a   Barros, Camila R ^a   Siqueira Catania, Antonela ^a   Ferreira, Sandra R G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ALLELE; ANTHROPOMETRY; ARTICLE; BRAZIL; CALORIC INTAKE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; DIET RESTRICTION; FAT MASS; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INSULIN BLOOD LEVEL; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE; AMINO ACID SUBSTITUTION; APOLIPOPROTEIN A-I; BRAZIL; CARDIOVASCULAR DISEASES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; PROLINE; PROMOTER REGIONS, GENETIC; PROTEINS; RISK FACTORS; RISK REDUCTION BEHAVIOR; YOUNG ADULT;

EID: 84877870854     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0055     Document Type: Article

References (53)

1. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med 2001;344:1343-1350.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346:393-403.
3. Esposito K, Ceriello A, Giugliano D. Diet and the metabolic syndrome. Metab Syndr Relat Disord 2007;5:291-295.
4. De Lorenzo A, Del Gobbo V, Premrov MG, et al. Normal-weight obese syndrome: Early inflammation? Am J Clin Nutr 2007;85:40-45.
5. Saravanan N, Haseeb A, Ehtesham NZ, et al. Differential effects of dietary saturated and trans-fatty acids on expression of genes associated with insulin sensitivity in rat adipose tissue. Eur J Endocrinol 2005;153:159-165.
6. Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-297.
7. Curti MLR, Jacob P, Borges MC, et al. Obesity, inflammation and dyslipidemia: implications for nutrigenetics. J Obes 2011; v2011:ID 497401.
8. Loos RJF, Bouchard C. The first gene contributing to common forms of human obesity. Obes Rev 2008;9:246-250.
9. Corella D, Ordovas JM. Nutrigenomics in cardiovascular medicine. Circ Cardiovasc Genet 2009;2:637-651.
10. Steinberg HO, Paradisi G, Hook G, et al. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000;49:1231-1238.
11. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006;6: 177-181.
12. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:996-1003.
13. Ramos RB, Casanova GK, Maturana MA, et al. Variations in the fat mass and obesity-associated (FTO) gene are related to glucose levels and higher lipid accumulation product in postmenopausal women from southern Brazil. Fertil Steril 2011;96:974-979.
14. Hinney A, Vogel CI, Hebebrand J. From monogenic to polygenic obesity: Recent advances. Eur Child Adolesc Psychiatry 2010;19;297-310.
15. Jones AB. Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond. Med Res Rev 2001;21:540-552.
16. Torra IP, Chinetti G, Duval C, et al. Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice. Curr Opin Lipidol 2001;12:245-254.
17. Danawati CW, Nagata M, Moriyama H, et al. A possible association of Pro12Ala polymorphism in peroxisome pro-liferator-activated receptor g 2 gene with obesity in native Javanese in Indonesia. Diabetes Metab Res 2005;21:465-469.
18. Tonjes A, Stumvoll M. The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk. Curr Opin Clin Nutr Metab Care 2007;10: 410-414.
19. Gouda HN, Sagoo GS, Harding A, et al. The association between the peroxisome proliferator-activated receptor-g2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mel-litus: A HuGE review and meta-analysis. Am J Epidemiol 2010;171:645-655.
20. Paul-Hayase H, Rosseneu M, Robinson D, et al. Polymorphisms in the apolipoprotein (apo) AI-CIII-AIV gene cluster: Detection of genetic variation determining plasma Apo AI, Apo CIII and Apo AIV concentrations. Hum Genet 1992;88:439-446.
21. Talmud PJ, Ye S, Humphries SE. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: The European Atherosclerosis Research Study. Genet Epidemiol 1994;11: 265-280.
22. Juo SH, Wyszynski DF, Beaty TH, et al. Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: A meta-analysis. Am J Med Genet 1999;82:235-241.
23. Lopez-Miranda J, Ordovas JM, Espino A, et al. Influence of mutation in human apolipoprotein A-1 gene promoter on plasma LDL cholesterol response to dietary fat. Lancet 1994;343:1246-1249.
24. Chen ES, Mazzotti DR, Furuya TK, et al. Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med 2009;9:319-325.
25. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: A consensus on Type 2 diabetes prevention. Diabetic Med 2007;24:451-463.
26. Craig CL, Marshall AL, Sjöström M, et al. International Physical Activity Questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381-1395.
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
28. Newton CR, Heptinstall LE, Summers C, et al. Amplification refractory mutation system for prenatal diagnosis and carrier assessment in cystic fibrosis. Lancet 1989;2:1481-1483.
29. Livak KJ, Flood SJ, Marmaro J, et al. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 1995;4:357-362.
30. Liang K-Y, Zeger SL. Longitudinal data analysis using Generalized Linear Models. Biometrika 1986;73:13-22.
31. He W. PPARg2 Polymorphism and human health. PPAR Res 2009;2009:849538.
32. HapMap (haplotype map of the human genome). http://www.ncbi.nlm.nih.gov/ SNP/.
33. Chen ES, Mazzotti DR, Furuya TK, et al. Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med 2009;9:319-325.
34. Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 2007;3: e115.
35. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007;316:889-894.
36. Steemburgo T, de Azevedo MJ, Gross JL, et al. The rs7204609 polymorphism in the fat mass and obesity-associated gene is positively associated with central obesity and micro-albuminuria in patients with type 2 diabetes from Southern, Brazil. J Ren Nutr 2012;22:228-236.
37. Ranjith N, Pegoraro RJ, Shanmugam R. Obesity-associated genetic variants in young Asian Indians with the metabolic syndrome and myocardial infarction. Cardiovasc J Afr 2011; 22:25-30.
38. Zimmermann E, Skogstrand K, Hougaard DM, et al. Influences of the common FTO rs9939609 variant on inflammatory markers throughout a broad range of body mass index. PLoS One 2011;6:e15958.
39. Lappalainen TJ, Tolppanen AM, Kolehmainen M, et al. Finnish Diabetes Prevention Study Group. The common variant in the FTO gene did not modify the effect of lifestyle changes on body weight: the Finnish Diabetes Prevention Study. Obesity 2009;17:832-836.
40. Delahanty LM, Pan Q, Jablonski KA, et al. Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care 2012;35:363-366.
41. Hotta K, Kitamoto T, Kitamoto A, et al. Association of variations in the FTO, SCG3 and MTMR9 genes with metabolic syndrome in a Japanese population. J Hum Genet 2011;56: 647-651.
42. Lappalainen T, Kolehmainen M, Schwab US, et al. Association of the FTO gene variant (rs9939609) with cardiovascular disease in men with abnormal glucose metabolism-the Finnish Diabetes Prevention Study. Nutr Metab Cardiovasc Dis 2011;21:691-698.
43. Mattevi VS, Zembrzuski VM, Hutz MH. Effects of a PPARG gene variant on obesity characteristics in Brazil. Braz J Med Biol Res 2007;40:927-932.
44. Morini E, Tassi V, Capponi D, et al. Interaction between PPARgamma2 variants and gender on the modulation of body weight. Obesity 2008;16:1467-1470.
45. Mirzaei H, Akrami SM, Golmohammadi T, et al. Polymorphism of Pro12Ala in the peroxisome proliferator-activated receptor gamma2 gene in Iranian diabetic and obese subjects. Metab Syndr Relat Disord 2009;7:453-458.
46. Frederiksen L, Brodbaek K, Fenger M, et al. Studies of the Pro12Ala polymorphism of the PPAR gamma gene in the Danish MONICA Cohort: Homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002;87:3989-3992.
47. Franks PW, Jablonski KA, Delahanty L, et al. Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 2007;50:2451-2460.
48. Milewicz A, Tworowska-Bardziñska U, Dunajska K. Relationship of PPAR gamma2 polymorphism with obesity and metabolic syndrome in postmenopausal Polish women. Exp Clin Endocrinol 2009;117:628-632.
49. Marchesi C, Schiffrin EL. Peroxisome proliferator-activated receptors and the vascular system: Beyond their metabolic effects. J Am Soc Hypertens 2008;2:227-238.
50. Passaro A, Dalla Nora E, Marcello C, et al. PPARg Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome. Cardiovasc Diabetol 2011;10:112.
51. Kim K, Lee S, Valentine RJ. Association of Pro12Ala polymorphism in the peroxisome proliferative-activated receptor gamma2 gene with obesity and hypertension in Korean women. J Nutr Sci Vitaminol 2007;53:239-246.
52. Yang LL, Hua Q, Liu RK, et al. Association between two common polymorphisms of PPARgamma gene and metabolic syndrome families in a Chinese population. Arch Med Res 2009;40:89-96.
53. Pagani F, Giudici GA, Baralle FE, et al. Association of a polymorphism in the Apo AI gene promoter with hyper-alphalipoproteinemia. Eur J Epidemiol 1992;S8:54-58.